|1.||Fondy, Thomas P: 1 article (08/2015)|
|2.||Trendowski, Matthew: 1 article (08/2015)|
|3.||White, Robert H: 1 article (05/2015)|
|4.||Xu, Huimin: 1 article (05/2015)|
|5.||Jones, Michael K: 1 article (05/2015)|
|6.||Ray, W Keith: 1 article (05/2015)|
|7.||Wang, Yu: 1 article (05/2015)|
|8.||Degani, H: 1 article (12/2013)|
|9.||Harris, T: 1 article (12/2013)|
|10.||Frydman, L: 1 article (12/2013)|
|1.||Dehydration (Water Stress)
09/01/1984 - "In the course of these studies it has been shown that the rate of hydration-dehydration of dihydroxyacetone phosphate at -24 degrees C was too slow to measure."
05/19/2015 - "A phosphate elimination reaction and a triose phosphate isomerase-like reaction occur at the GA-3-P binding site I and II, respectively, prior to the aldol condensation between the enzyme-bound enol form of methylglyoxal and dihydroxyacetone phosphate (DHAP), after which the catalytic cycle is completed by a cyclization and two dehydration reactions assisted by several general acids/bases at the same active site."
|2.||Zellweger Syndrome (Zellweger's Syndrome)
05/01/1987 - "Acylation of dihydroxyacetone phosphate by control cell homogenate was stimulated by N-ethylmaleimide at both pH 5.7 and 7.5 whereas this activity from Zellweger syndrome cells was slightly inhibited at pH 5.7 and strongly inhibited at pH 7.5. "
10/25/1984 - "We measured the activity of dihydroxyacetone phosphate (DHAP) acyltransferase, a peroxisomal enzyme with a major role in ether lipid synthesis, in fibroblasts and leukocytes from patients with Zellweger syndrome. "
05/01/1987 - "Judging from their Km and Vmax values, glycerol phosphate acyltransferase (EC 22.214.171.124), acyl/alkyl dihydroxyacetone phosphate reductase (EC 126.96.36.199), and acyl coenzyme A reductase (long-chain alcohol forming), appear to be affected only slightly by the absence of peroxisomes characteristic of the Zellweger syndrome. "
08/01/2015 - "The effects of plasma membrane alkylating agents may be further potentiated through the use of another novel class of chemotherapeutic agents, known as dihydroxyacetone phosphate (DHAP) inhibitors, since many cancer types are known to rely on the DHAP pathway for lipid synthesis. "
03/24/1975 - "The relative utilization of the acyl dihydroxyacetone phosphate and glycerol phosphate pathways for synthesis of glycerolipids in various tumors and normal tissues."
|4.||Ehrlich Tumor Carcinoma
02/01/1971 - "The acyl-dihydroxyacetone phosphate pathway plays a significant role in glycerolipid synthesis in mouse liver homogenates and a clearly dominant one in Ehrlich ascites tumor cell homogenates. "
02/01/1971 - "The acyl dihydroxyacetone phosphate pathway for glycerolipid biosynthesis in mouse liver and Ehrlich ascites tumor cells."
01/10/1981 - "Hydrogen exchange in the formation of dihydroxyacetone phosphate from acyl dihydroxyacetone phosphate in O-alkyl lipid synthesis in Ehrlich ascites tumor cell microsomes."
04/01/1994 - "In the liver under basal conditions, uremia markedly decreased levels of glycogen, F-1,6-diphosphate (F-1,6-diP), F-2,6-diP, 3-glycero-phosphate (3-glycero-P), dihydroxyacetone phosphate (DHAP), pyruvate, lactate, and adenosine triphosphate (ATP), and the phosphorylation state (ATP/adenosine diphosphate [ADP] x inorganic phosphorus [PI]), increased phosphoenolpyruvate (PEP), ADP, and Pi levels, but did not affect the cytosolic redox state (pyruvate/lactate). "
|2.||Pyruvic Acid (Pyruvate)
|4.||Triose-Phosphate Isomerase (Triosephosphate Isomerase)
|8.||Adenosine Triphosphate (ATP)
|9.||alpha-glycerophosphoric acid (sodium glycerophosphate)
|10.||Citric Acid (Citrate)